PE20050245A1 - Antagonistas de nmda/nr2b nonaril - heterociclicos n-sustituidos - Google Patents
Antagonistas de nmda/nr2b nonaril - heterociclicos n-sustituidosInfo
- Publication number
- PE20050245A1 PE20050245A1 PE2004000552A PE2004000552A PE20050245A1 PE 20050245 A1 PE20050245 A1 PE 20050245A1 PE 2004000552 A PE2004000552 A PE 2004000552A PE 2004000552 A PE2004000552 A PE 2004000552A PE 20050245 A1 PE20050245 A1 PE 20050245A1
- Authority
- PE
- Peru
- Prior art keywords
- aril
- pyrimidin
- fluoro
- methyl
- nonaryl
- Prior art date
Links
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 title 1
- 102000034527 Retinoid X Receptors Human genes 0.000 title 1
- 108010038912 Retinoid X Receptors Proteins 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- WCYWZMWISLQXQU-UHFFFAOYSA-N methyl Chemical class [CH3] WCYWZMWISLQXQU-UHFFFAOYSA-N 0.000 abstract 3
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical compound BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 abstract 2
- DNUTZBZXLPWRJG-UHFFFAOYSA-M piperidine-1-carboxylate Chemical compound [O-]C(=O)N1CCCCC1 DNUTZBZXLPWRJG-UHFFFAOYSA-M 0.000 abstract 2
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 abstract 1
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 abstract 1
- 208000000094 Chronic Pain Diseases 0.000 abstract 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 abstract 1
- 206010065390 Inflammatory pain Diseases 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- XIPUIGPNIDKXJU-UHFFFAOYSA-N [CH]1CC1 Chemical compound [CH]1CC1 XIPUIGPNIDKXJU-UHFFFAOYSA-N 0.000 abstract 1
- 229910052794 bromium Inorganic materials 0.000 abstract 1
- 229910052801 chlorine Inorganic materials 0.000 abstract 1
- 239000000460 chlorine Substances 0.000 abstract 1
- 230000001684 chronic effect Effects 0.000 abstract 1
- 229910052731 fluorine Inorganic materials 0.000 abstract 1
- 239000011737 fluorine Substances 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 229910052740 iodine Inorganic materials 0.000 abstract 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 abstract 1
- 239000011630 iodine Substances 0.000 abstract 1
- 208000004296 neuralgia Diseases 0.000 abstract 1
- 208000021722 neuropathic pain Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- LJXQPZWIHJMPQQ-UHFFFAOYSA-N pyrimidin-2-amine Chemical compound NC1=NC=CC=N1 LJXQPZWIHJMPQQ-UHFFFAOYSA-N 0.000 abstract 1
- 230000009278 visceral effect Effects 0.000 abstract 1
- 208000009935 visceral pain Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Virology (AREA)
- Addiction (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Molecular Biology (AREA)
- Ophthalmology & Optometry (AREA)
- Psychology (AREA)
- Biotechnology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
Abstract
REFERIDA A UN COMPUESTO DE FORMULA I DONDE HetAr ES UN ANILLO HETEROAROMATICO CON 1-2 ATOMOS DE N EN EL ANILLO, TIAZOLILO, TIADIAZOLILO; HetAr ESTA OPCIONALMENTE TIENE 1-2 SUSTITUYENTES TALES COMO ALQUILC1-C4, FLUORO, CLORO; BROMO, YODO; A ES UN ENLACE O ALQUIL-C1-C2; B ES ARIL(CH2)0-3-O-C(O)-, ARIL(CH2)1-3-C(O)-, ARIL-CICLOPROPIL-C(O)-, ENTRE OTROS. TAMBIEN REFERIDA A UNA COMPOSICION FARMACEUTICA QUE CONTIENE DICHO COMPUESTO CUYOS PREFERIDOS SON: (3R,4S)3-FLUORO-4-[(PIRIMIDIN-2-ILAMINO)METIL]PIPERIDINA-1-CARBOXILATO DE 4-METILBENCILO; 3-FLUORO-4-[(PIRIMIDIN-2-ILAMINO)METIL]PIPERIDINA-1-CARBOXILATO DE (-)-TRANS-4-METILBENCILO Y (3R,4S)-N-[(3-CIS-FLUORO-1-{[(1R,2R)-2-FENILCICLOPROPIL]CARBONIL}PIPERIDIN-4-IL)METIL]PIRIMIDIN-2-AMINA; ENTRE OTROS. DICHOS COMPUESTOS SON UTILES EN EL TRATAMIENTO DE LA ENFERMEDAD DE PARKINSON, DE DOLORES CRONICOS, VISCERALES, INFLAMATORIOS Y NEUROPATICOS, ENTRE OTROS
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US47593803P | 2003-06-04 | 2003-06-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20050245A1 true PE20050245A1 (es) | 2005-04-13 |
Family
ID=33511734
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2004000552A PE20050245A1 (es) | 2003-06-04 | 2004-06-01 | Antagonistas de nmda/nr2b nonaril - heterociclicos n-sustituidos |
Country Status (30)
| Country | Link |
|---|---|
| EP (1) | EP1648882B1 (es) |
| JP (1) | JP3927228B2 (es) |
| KR (1) | KR20060017839A (es) |
| CN (1) | CN1798744A (es) |
| AR (1) | AR044579A1 (es) |
| AT (1) | ATE403651T1 (es) |
| AU (1) | AU2004245522B2 (es) |
| BR (1) | BRPI0410837A (es) |
| CA (1) | CA2527093C (es) |
| CL (1) | CL2004001365A1 (es) |
| CO (1) | CO5700762A2 (es) |
| DE (1) | DE602004015610D1 (es) |
| DK (1) | DK1648882T3 (es) |
| EC (1) | ECSP056192A (es) |
| ES (1) | ES2309540T3 (es) |
| HR (1) | HRP20080490T3 (es) |
| IS (1) | IS8117A (es) |
| MA (1) | MA27781A1 (es) |
| MX (1) | MXPA05013151A (es) |
| MY (1) | MY138547A (es) |
| NO (1) | NO20060020L (es) |
| PE (1) | PE20050245A1 (es) |
| PL (1) | PL1648882T3 (es) |
| PT (1) | PT1648882E (es) |
| RU (1) | RU2339630C2 (es) |
| SI (1) | SI1648882T1 (es) |
| TW (1) | TW200510378A (es) |
| UA (1) | UA81319C2 (es) |
| WO (1) | WO2004108705A1 (es) |
| ZA (1) | ZA200509000B (es) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2007247851A1 (en) * | 2006-05-03 | 2007-11-15 | Relevare Aust. Pty Ltd | Methods and composition for treatment of inflammatory pain |
| MX2009011416A (es) * | 2007-04-23 | 2009-11-05 | Janssen Pharmaceutica Nv | Tia(di)azoles como antagonistas del receptor de dopamina 2 de disociacion rapida. |
| US20100316678A1 (en) * | 2007-06-28 | 2010-12-16 | Cnsbio Pty Ltd. | Combination methods and compositions for treatment of neuropathic pain |
| CN102762554A (zh) | 2010-02-16 | 2012-10-31 | 辉瑞大药厂 | 5-ht4受体的部分激动剂(r)-4-((4-((4-(四氢呋喃-3-基氧基)苯并[d]异*唑-3-基氧基)甲基)哌啶-1-基)甲基)四氢-2h-吡喃-4-醇 |
| CA2869216A1 (en) | 2012-04-20 | 2013-10-24 | Ucb Pharma S.A. | Methods for treating parkinson's disease |
| CN103936663B (zh) * | 2013-01-23 | 2016-12-28 | 艾琪康医药科技（上海）有限公司 | 一种1-r1-3,3-二氟(或3-氟)-4-r2-4-氨甲基哌啶及其衍生物的制备方法 |
| US9221796B2 (en) | 2014-01-09 | 2015-12-29 | Bristol-Myers Squibb Company | Selective NR2B antagonists |
| US9187506B2 (en) | 2014-01-09 | 2015-11-17 | Bristol-Myers Squibb Company | (R)-3-((3S,4S)-3-fluoro-4-(4-hydroxyphenyl)piperidin-1-yl)-1-(4-methylbenzyl)pyrrolidin-2-one and its prodrugs for the treatment of psychiatric disorders |
| CN106795163B (zh) | 2014-06-04 | 2019-07-30 | 卢郡控股(开曼)有限公司 | 作为nr2b nmda受体拮抗剂的二氟乙基吡啶衍生物 |
| KR102569031B1 (ko) | 2014-09-15 | 2023-08-22 | 뤼겐 홀딩스 (케이맨) 리미티드 | Nr2b nmda 수용체 길항제로서의 피롤로피리미딘 유도체 |
| WO2016049048A1 (en) * | 2014-09-22 | 2016-03-31 | Rugen Holdings (Cayman) Limited | Treatment of anxiety disorders and autism spectrum disorders |
| ES2939296T3 (es) | 2014-12-23 | 2023-04-20 | Avalo Therapeutics Inc | Compuestos, composiciones y métodos |
| EP3253761A4 (en) | 2015-02-04 | 2018-06-20 | Rugen Holdings (Cayman) Limited | 3,3-difluoro-piperidine derivatives as nr2b nmda receptor antagonists |
| WO2016196513A1 (en) | 2015-06-01 | 2016-12-08 | Rugen Holdings (Cayman) Limited | 3,3-difluoropiperidine carbamate heterocyclic compounds as nr2b nmda receptor antagonists |
| AU2016340239A1 (en) | 2015-10-14 | 2018-05-31 | Bristol-Myers Squibb Company | Selective NR2B antagonists |
| BR112018006537A2 (pt) | 2015-10-14 | 2018-10-16 | Bristol-Myers Squibb Company | antagonistas seletivos de nr2b |
| CA3021675C (en) | 2016-08-31 | 2024-06-25 | Eisai R&D Management Co., Ltd. | Pyrazolo[1,5-a]pyrimidine compound |
| WO2018098128A1 (en) | 2016-11-22 | 2018-05-31 | Rugen Holdings (Cayman) Limited | Treatment of autism spectrum disorders, obsessive-compulsive disorder and anxiety disorders |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA75392C2 (en) * | 2001-02-23 | 2006-04-17 | Merck & Co Inc | N-substituted non-aryl heterocyclic antagonists nmda/nr2b |
-
2004
- 2004-05-28 MX MXPA05013151A patent/MXPA05013151A/es active IP Right Grant
- 2004-05-28 BR BRPI0410837-0A patent/BRPI0410837A/pt not_active IP Right Cessation
- 2004-05-28 ES ES04753896T patent/ES2309540T3/es not_active Expired - Lifetime
- 2004-05-28 DE DE602004015610T patent/DE602004015610D1/de not_active Expired - Lifetime
- 2004-05-28 CN CNA2004800153228A patent/CN1798744A/zh active Pending
- 2004-05-28 CA CA002527093A patent/CA2527093C/en not_active Expired - Lifetime
- 2004-05-28 KR KR1020057023218A patent/KR20060017839A/ko not_active Ceased
- 2004-05-28 DK DK04753896T patent/DK1648882T3/da active
- 2004-05-28 UA UAA200511411A patent/UA81319C2/uk unknown
- 2004-05-28 SI SI200430845T patent/SI1648882T1/sl unknown
- 2004-05-28 AU AU2004245522A patent/AU2004245522B2/en not_active Expired
- 2004-05-28 EP EP04753896A patent/EP1648882B1/en not_active Expired - Lifetime
- 2004-05-28 JP JP2006515051A patent/JP3927228B2/ja not_active Expired - Lifetime
- 2004-05-28 RU RU2005137704/04A patent/RU2339630C2/ru not_active IP Right Cessation
- 2004-05-28 HR HR20080490T patent/HRP20080490T3/xx unknown
- 2004-05-28 AT AT04753896T patent/ATE403651T1/de not_active IP Right Cessation
- 2004-05-28 WO PCT/US2004/017175 patent/WO2004108705A1/en not_active Ceased
- 2004-05-28 PL PL04753896T patent/PL1648882T3/pl unknown
- 2004-05-28 PT PT04753896T patent/PT1648882E/pt unknown
- 2004-05-31 AR ARP040101878A patent/AR044579A1/es unknown
- 2004-05-31 MY MYPI20042091A patent/MY138547A/en unknown
- 2004-06-01 PE PE2004000552A patent/PE20050245A1/es not_active Application Discontinuation
- 2004-06-03 TW TW093115972A patent/TW200510378A/zh unknown
- 2004-06-03 CL CL200401365A patent/CL2004001365A1/es unknown
-
2005
- 2005-11-07 IS IS8117A patent/IS8117A/is unknown
- 2005-11-07 ZA ZA200509000A patent/ZA200509000B/en unknown
- 2005-11-28 MA MA28626A patent/MA27781A1/fr unknown
- 2005-11-29 EC EC2005006192A patent/ECSP056192A/es unknown
- 2005-11-30 CO CO05121658A patent/CO5700762A2/es not_active Application Discontinuation
-
2006
- 2006-01-03 NO NO20060020A patent/NO20060020L/no not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20050245A1 (es) | Antagonistas de nmda/nr2b nonaril - heterociclicos n-sustituidos | |
| EA200400971A1 (ru) | Фторзамещенные циклоалканоиндолы, композиции, содержащие такие соединения, и способы лечения | |
| PE20081506A1 (es) | Formulaciones de ansamicina | |
| EA200500392A1 (ru) | Производные пиримидина и их применение в качестве модуляторов св2 | |
| EA200401194A1 (ru) | Миметики глюкокортикоидов, способы их получения, фармацевтические композиции и их применение | |
| DK1663206T3 (da) | 1-(2,3-dimethyl-phenyl)-ethyl-1,3-dihydro-imizadol-2-thion som ikke-sedativ alpha 2A-agonist | |
| PE20220937A1 (es) | Compuestos macrociclicos como agonistas de sting y metodos y usos de los mismos | |
| UY27774A1 (es) | Inhibidores de metaloproteinas de triaril-oxi-aril-espiropirimidina-2,4,6-triona | |
| ATE418548T1 (de) | Substituierte 3-cyanothiophen acetamide als glucagon receptor antagonisten | |
| EA200870535A1 (ru) | СПОСОБЫ ЛЕЧЕНИЯ АУТОИММУННЫХ ЗАБОЛЕВАНИЙ С ИСПОЛЬЗОВАНИЕМ СЛИТОЙ МОЛЕКУЛЫ TACI-Ig | |
| CL2008001820A1 (es) | Compuestos derivados de aril-isoxasol-imidazol; procedimiento de preparacion; composicion farmaceutica que los contiene; y uso en la preparacion de medicamentos utiles en el tratamiento de trastornos cognitivos y enfermedades relacionadas con alzheimer. | |
| CY1110913T1 (el) | Παραγωγα 2-πυρρολιδιν-2-υλο-[1,3,4]-οξαδιαζολης και η χρησιμοποιηση τους σαν αντικαταθλιπτικα | |
| PE20060585A1 (es) | Derivados de 2-amido-4-feniltiazol como antagonistas de quimiocinas y su preparacion | |
| PE20250558A1 (es) | Compuestos, procedimiento de obtencion de los compuestos, composicion farmaceutica, uso de los compuestos y metodo de tratamiento de desordenes psiquiatricos y/o trastornos del sueno | |
| EA201300826A1 (ru) | Применение димирацетама для лечения остеоартрита и связанных с ним заболеваний | |
| BRPI0412905A (pt) | composição farmacêutica como forma de dosagem sólida e método de fabricação | |
| PE20061318A1 (es) | Nuevas combinaciones terapeuticas para el tratamiento o la prevencion de trastornos psicoticos | |
| NO20082181L (no) | Formuleringer av Fispemifen | |
| EA200501046A1 (ru) | Эсциталопрамгидробромид и способ его получения | |
| TW200722420A (en) | Propane-1,3-dion derivative or salt thereof | |
| PE20061418A1 (es) | Composiciones farmaceuticas de 4-[(ciclopropanocarbonilamino)metil]-2-(2,6-dioxopiperidin-3-il)isoindol-1,3-diona para el tratamiento o prevencion de lupus cutaneo | |
| AR038632A1 (es) | Composicion farmaceutica | |
| EA200701601A1 (ru) | Антигельминтные производные имидазола и тиазола | |
| TW200621223A (en) | Acyclic 1,3-diamines and uses therefor | |
| TW200500376A (en) | Novel adenosine analogues and their use as pharmaceutical agents |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration | ||
| FD | Application declared void or lapsed |